

Appropriations - FY 2018

- Deadline September 30, 2018
- Continuing Resolution to Dec. 7th (Lame Duck)
- Minibuses
 - Energy-Water, Legislative Branch and Military Construction-VA
 - Interior-Environment, Financial Services, Transportation-HUD and Agriculture
 - Defense and Labor-HHS-Education
- Future of Appropriations Process 2 year cycle?
- Bring back Earmarks

Buchanan Ingersoll & Rooney PC 2

340B Drug Discount Program

- ASP minus 22.5% (cut 28.5%)
- Savings must be redistributed equally to hospitals covered under OPPS.
- Divisions among Pharma, Hospitals, Community Oncologists
- Legislation: Ranges from reversing the cut to transparency of dollars
- Lawsuits (AHA)

Buchanan Ingersoll & Rooney № 3

Opioid Efforts (HR 6) ■ How to address the Opioid Epidemic? ■ House bill passed on June 22, 2018 ■ Senate bill passed the week of September 17th ■ Topic Areas of HR 6 ■ Treatment and Recovery ■ Prevention ■ Protecting Communities ■ Fighting Fentanyl ■ Will it even help????????? Buchanan Ingersoll & Roonev № 4 Physician Fee Schedule - CY 2019 Just to name a few provisions: • Eliminates prohibition on same day visits ■ E/M Documentation Redundancy ■ Teaching Physician Simplification Interoperability ■ Price Transparency Buchanan Ingersoll & Rooney PC 5 Stark Self Referral ■ CMS Request for Information: ■ June 25th (comments were due by August 24th) ■ 20 separate topics ■ Ways and Means Health Subcommittee "Modernizing Stark Law to Ensure the Successful Transition from Volume to Value in the Medicare Program" ■ Issues related to compliance and barriers ■ How should it be modified Buchanan Ingersoll & Rooney № 6

Drug Pricing: White House Team

- Fulfilling campaign pledge to address drug prices
- To do so, needed "A" team at Department of Health & Human Services
 - Sec. Azar former Eli Lilly President of U.S. Operations
 - Dan Best, Sr. Adv. For Drug Pricing Reform former CVS Part D
 - John O'Brien, Advisor to the Secretary, Pharmacist and former Insurance Policy Advisor

Deep understanding of the drug pricing and supply chain Working to implement the "low hanging fruit" first

Buchanan Ingersoll & Rooney PG 7

Blueprint to Lower Drug Prices and Reduce OoP Costs

- Divided into two categories:
 - Actions President may direct HHS to take immediately
 - Actions being considered by HHS requested feedback
 - Actions divided in the following areas:
 - Increased Competition
 - Better Negotiation
 - Incentives to Lower List Prices
 - Lowering Out-of-Pocket Costs

Buchanan Ingersoll & Rooney PC 8

Public's View on How to help community Which factor has the greatest impact on improving health care in your community? 51% Lower-cost Flexibility to see providers after hours Convenient health care facilities Source Crishadh Bachanan Ingersoll & Rooney PK | 9

Lower List Price (Transparency)

- List individual Rx price on CMS Drug Dashboard
- Durbin/Grassley amendment to LHHS Approps: \$1M to implement List Price incorporated in TV Ads
- Upcoming Rule regarding Medicare and Medicaid Drug Pricing Transparency
- Public Shaming Pfizer (or was it?)

Buchanan Ingersoll & Roonev № 10

Competition and Negotiation

- Step Therapy for Part B Drugs in Medicare Advantage Begins Jan. 1, 2019
- Working group to examine Drug Importation
- Generic Drug Approvals since Blue Print released "record number in July"
 2017: over 1,000 total July 2018: 126 total
- CREATES Act and May public shaming of branded drugs impeding access to samples

Buchanan Ingersoll & Rooney rc 11

Buchanan Ingersoll & Rooney PC


Out-of-Pocket Knowledge Do you typically know the out-of-pocket cost for a medication before you fill the prescription? 59% No Source CVS Heath

Out-of-Pocket Costs

- Revoke pharmacy "gag clauses" for Part D- supportive of more expansive
- 340B inpatient and outpatient ----big turf battle
- Lots of vague talk


Buchanan Ingersoll & Rooney PC 13

How the Industry views Drug Distribution



Buchanan Ingersoll & Roonev №

How the White House views Drug Distribution



Buchanan Ingersoll & Rooney PC

PBMs

- Political Landscape
 - White House
 - Congress
- PBMs vs the World (almost)
- \blacksquare Rebates reduced costs in Part D by \$34.9B and w/out premiums $\uparrow 52\%$ in 2018 (Oliver Wyman Consulting)
- "This study further confirms that drugmakers set and raise prices unrelated to the rebates they negotiate with PBMs. Drug companies keep raising prices even when rebates go down, "said PCMA President and CEO Mark Merritt." Simpley eliminating plans ability to negotiate price concessions would enrich drugmakers at the expense of patients, who'd not only face higher prices but higher premiums and out-of-pocket costs too."

Buchanan Ingersoll & Rooney № 16

115th Congressional Party Breakdown House Senate 435 100 193 Democrats - 237 Republicans - 6 Vacancies 49 Democrats (including 2 "Independents") 51 Republicans Democrats need a net gain of 22 seats to flip control of Democrats need a net gain of 2 seats to flip control of the Senate the House. Buchanan Ingersoll & Rooney № 17

November Mid-Term Elections: House

- According to Cook Political Report, 11 Republican seats are "likely" or "lean" Democratic.
- Another 28 Republican Seats are "toss-ups".
 Currently, only one Democratic seat is in danger of flipping Republican (Pennsylvania 14); only 2 Democratic seats are "toss-ups".
- Nate Silver's FiveThirtyEight gives Democrats a 82.9% chance of winning control of the House; Republicans have a 17.1% chance of retaining control.



November Mid-Term Elections: Senate



- 35 Senate seats are up for election in 2018 (including special elections in Minnesota and Mississippi).
- Of the 35 Senate seats, 26 are currently held by Democrats including in 5 states that Trump won by double digits.

Buchanan Ingersoll & Rooney № 20

Senate: Competitive Seats TOSS-UP/POTENTIALLY COMPETITIVE SEATS (in order of most competitive/likely to flip) STATE INCUMBENT TRUMP 2016 AZ Jeff flake (retiring) 1-2.5% AZ Jeff flake (retiring) 1-3.6% MO Claire McCaskiii (D-MO) 1-38.5% N De Donnelly (D-NN) 1-30.5% N De Marchill (D-MO) 1-3.5% N De Marchil

Buchanan Ingersoll & Rooney № 21

Pennsylvania's Most Watched List

- Seven Freshman Representatives
 - New 4th District, Meehan, Costello, Dent, Barletta, Shuster, Murphy
 - Rep. Rothfus vs. Rep. Conor Lamb
 - Other matchups Sleepers?
 - Rep. Carthwright vs. John Chrin
 - Rep. Kelly vs. Ron DiNicola
 - Rep. Perry vs. George Scott


Buchanan Ingersoll & Rooney PC 22

What is "lobbying"

- ✓ Education!!
- √ Substantive policy expertise
- ✓ Political insight and access
- ✓ Creative problem-solving
- ✓ Play nice
- ✓ Ethical obligations

Buchanan Ingersoll & Rooney № 23

Phases of GR Introduce organization to Isamakes Initiate and begin building relationships Core up policy issues important to the organization Protected of calling the Hill, the Hill cells YOU Internating relationship by providing operation Protected of calling the Hill, the Hill cells YOU Internating relationship by providing operation Protection on Protection on Internation and line edits to proposed legislation Itsus intervention Seek intervention on specific ron-legislative issues from Members of Congress Regulatory or Administrative input Buchanan Ingensoil & Rooney're



3 Actions to Take to Maximize your Agenda	
Advocate	
Collaborate	
[Ideate	
Buchanan Ingersoll 4 Rooney ≈ 25	